Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalo myelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cann...

Full description

Saved in:
Bibliographic Details
Published in:Brain (London, England : 1878) England : 1878), 2003-10, Vol.126 (10), p.2191-2202
Main Authors: Pryce, Gareth, Ahmed, Zubair, Hankey, Deborah J. R., Jackson, Samuel J., Croxford, J. Ludovic, Pocock, Jennifer M., Ledent, Catherine, Petzold, Axel, Thompson, Alan J., Giovannoni, Gavin, Cuzner, M. Louise, Baker, David
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalo myelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice deficient in the cannabinoid receptor CB1 tolerate inflammatory and excito toxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB1 agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.
ISSN:0006-8950
1460-2156
DOI:10.1093/brain/awg224